Abstract
This review offers an informed insight on the pathophysiology of ocular cicatricial pemphigoid in addition to up-to-date recommendations for monitoring and management. Systemic immunosuppression is required for treatment of ocular cicatricial pemphigoid when there is high suspicion, even in the absence of diagnostic findings on biopsy. New therapeutic modalities continue to emerge and provide promising results. In addition, improved options for adjunctive care are also available. Ocular cicatricial pemphigoid is a systemic illness and a subset of mucous membrane pemphigoid that primarily affects the ocular surface. It involves a progressive and potentially blinding course of disease. Diagnosis remains challenging and mainly depends on clinical suspicion with the aid of laboratory testing. Multiple treatment modalities have emerged for management mainly consisting of systemic immunosuppression for disease control in addition to adjunctive management for alleviating symptoms and preventing complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
